Beatrix Benz

📌Gunnar Schroefel about the impact of the #europeancancersummit , the most pressing issue in oncology and his opinion of #OncoDaily European Cancer Organisation Daiichi Sankyo Europe GmbH #Cancer #GlobalOncology #Healthcare #MedNews #Health #Medicine #OncoDaily #Oncology

14

The Rare Disease Action Forum brings together voices from actors in the field of rare diseases representing the industry, healthcare professionals, patient and research organizations to improve the lives of patients with rare diseases in Switzerland. Our objectives include: 👉 Raising awareness about rare diseases in Switzerland and foster dialogue about patients’ needs 👉 Assessing and adapting the Swiss environment to the needs of patients with rare diseases 👉 Adapting the standards to enable equal and fair treatment for patients with rare diseases Join our multi-stakeholder association or discover more RDAF objectives: https://bit.ly/3nKB4B1 #rarediseases #Switzerland

4

+++ 𝗤𝟭 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝟮𝟬𝟮𝟰 𝗮𝗻𝗱 𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲 𝘂𝗽𝗱𝗮𝘁𝗲 +++ We started the year with good progress across our oncology pipeline and our commercialization activities. Some key events: 🔬 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆: We and our collaboration partner Duality Biologics dosed the first patient in a Phase 3 clinical trial with our #ADC candidate BNT323/DB-1303 in breast cancer patients, advancing towards BioNTech’s goal of ten or more potentially registrational trials running by the end of 2024. 🩹 𝗖𝗢𝗩𝗜𝗗-𝟭𝟵: We are focusing on preparing for variant-strain adaptation of our COVID-19 vaccine to be ready for a commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals. 🌎 𝗖𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝗿𝗲𝗮𝗱𝗶𝗻𝗲𝘀𝘀: We appointed our General Manager Fatma Ocak for the U.S. in line with our commercial preparations to drive our first expected global #oncology product launch. 𝗟𝗶𝗻𝗸 𝘁𝗼 𝗣𝗥 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀: https://lnkd.in/ePDQiHbH  

550

2 Kommentare

Oncobit AG, a Schlieren-based cancer precision medicine company, has closed a Pre-Series A financing round, raising a total of CHF 1.47 million from existing and new investors. The capital will flow into product development and growth plans.  Claudia Scheckel Oncobit AG Bram Goorden IXICO #precisionmedicine #diagnostics #oncology https://lnkd.in/esjWY5dK

25

Discover the Latest Regulatory Insights! 📈📘 Stay informed with the May 2024 edition of the Swissmedic Journal, your authoritative source for therapeutic product regulations in Switzerland. This month’s issue is packed with essential updates and expert analyses that are crucial for healthcare professionals and industry stakeholders. 🔍 Inside This Edition: - Updates on new drug regimens and market regulations - An index of medicinal products with new or modified indications - Critical information on authorizations and withdrawals - Don’t miss out on the knowledge that could shape your strategic decisions! #SwissmedicJournal #HealthcareRegulation #PharmaceuticalInsights

5

Transforming Swiss medicine: b-rayZ at the SP Health Colloquium in Bern🇨🇭 We are pleased to announce that b-rayZ's CEO, Cristina Rossi, will participate as a featured speaker at this year's SP Health Colloquium, scheduled for May 3rd at the Bundeshaus in Bern. This event is pivotal in discussing the integration of artificial intelligence within healthcare, with a focus on the legal, ethical, and practical dimensions. Cristina's presentation, titled "Breast Cancer Early Detection Through AI," will explore how digitalization is transforming Swiss medicine, demonstrating b-rayZ's leadership in applying AI for improved diagnostics. Her insights will underscore the growing necessity for digital tools in enhancing patient outcomes and streamlining medical processes in Switzerland. Discussions will revolve around the importance of creating transparent, safe, and well-regulated frameworks to foster the large-scale adoption of these technologies. Such frameworks are crucial for ensuring that advancements in AI are both effective and ethically implemented. b-rayZ is committed to leading by example, showing how thoughtful regulation and cutting-edge technology can coexist to revolutionize healthcare. We look forward to engaging with policymakers and industry leaders to further this cause. 🙌 #bern #ai #medicine #healthcare #swiss #artificialintelligence #medtech

24

Today, the European Medicines Agency recommended not granting a marketing authorisation for Leqembi (lecanemab). The main reason for that decision was, according to the EMA statement, that "the observed effect of Leqembi on delaying cognitive decline does not counterbalance the risk of serious side events associated with the medicine, in particular the frequent occurrence of amyloid-related imaging abnormalities (ARIA), involving swelling and potential bleedings in the brain of patients who received Leqembi." You can see more details about the EMA statement at their website. At Ace Alzheimer Center Barcelona we believe this decision entails major concerns for the clinical, medical, and care community as well as for the field of research. First, the access of European patients to the same options and opportunities as the citizens from other countries. Secondly, the effect it can have in terms of research and investment in research. See more of our position in the open letter we sent to the EMA representatives: https://lnkd.in/d46T7fMt #Lecanemab #EMA #Leqembi #Alzheimers

58

1 Kommentar

During #ECRD2024, we had the privilege of presenting a poster highlighting insights from our comprehensive study evaluating the economic impact of rare diseases in France, Germany and Italy. Our analysis reinforces the urgent need for policies that advance access to treatments in order to address the significant economic burden that rare diseases impose on individuals, society and healthcare systems. We are pleased to share that abstracts from the 12th ECRD conference are now available in the Orphanet Journal of Rare Diseases. To learn more about our key findings, see Section P26 in the meeting abstract here: https://lnkd.in/eh4eF8Sd EURORDIS-Rare Diseases Europe #RareDiseases #ChiesiGlobalRareDiseases

79

1 Kommentar

EURORDIS is calling upon the EU’s next set of policymakers to #ActRare2024! 📣 But what drives this call for action? What specific improvements are we seeking to achieve? What does this mean for Europe’s patients and families living with rare diseases? Meet Reinhard Pell, Founder and Chair of the patient organisation Cure MCOPS12, which he established in 2020 following his son Simon’s diagnosis with the ultra-rare disease MCOPS12. We delve into these questions through the experiences and challenges his family have faced over the years, such as financial hurdles, the process of obtaining a diagnosis, and the lack of research and treatments available for many rare diseases. Discover how our Act Rare policy asks relate to Reinhard and how they could improve the health and wellbeing of families like his. Read the full article now 👉 https://lnkd.in/evsm2hbE #RareDiseases #Europe #PatientStory #community #elections

21

🌟 𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 "𝗙𝗿𝗶𝗲𝗻𝗱𝘀 𝗼𝗳 𝗦𝗵𝗮𝗿𝗲𝗠𝗲𝗱": 𝗝𝗼𝗶𝗻 𝗨𝘀 𝗶𝗻 𝗠𝗮𝗸𝗶𝗻𝗴 𝗮 𝗗𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲! 🌟 We at ShareMed Swiss are thrilled to announce the launch of our supporters network, "Friends of ShareMed"! As we continue our mission to redistribute unused medicines and medical devices to those in need, we’re calling on our dedicated followers and supporters to join us in this crucial effort. 𝗪𝗵𝗮𝘁 𝗪𝗲 𝗡𝗲𝗲𝗱: 📦 𝗜𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 𝗮𝗯𝗼𝘂𝘁 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 𝗮𝗻𝗱 𝗗𝗲𝘃𝗶𝗰𝗲𝘀 𝗳𝗼𝗿 𝗗𝗼𝗻𝗮𝘁𝗶𝗼𝗻: Help us identify available medicines and medical devices that can be donated before their expiry date. 🔗 𝗖𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝗞𝗲𝘆 𝗦𝘁𝗮𝗸𝗲𝗵𝗼𝗹𝗱𝗲𝗿𝘀: Assist us in connecting with wholesalers, hospitals, and other medical institutions. We aim to understand their motivations and current cost structures related to unused soon-to-expire medicines and unused medical devices. 📣 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗶𝗻 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗘𝘃𝗲𝗻𝘁𝘀: Contribute to our communication efforts, help organize events, spread the word about our activities, and attract more supporters to our cause. By joining "𝗙𝗿𝗶𝗲𝗻𝗱𝘀 𝗼𝗳 𝗦𝗵𝗮𝗿𝗲𝗠𝗲𝗱", you can make a tangible impact. Those who register will have the opportunity to be featured in our gallery of supporters on our homepage, showcasing their commitment to our mission. 𝗢𝘂𝗿 𝗩𝗶𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝗠𝗶𝘀𝘀𝗶𝗼𝗻: At ShareMed Swiss, we envision a world where unused medicines and medical devices are efficiently redistributed to those who need them, thus saving costs and protecting the environment from waste. Our mission is to identify and facilitate the donation of these products, ensuring they reach those in need, no matter where they are. 𝗪𝗵𝘆 𝗝𝗼𝗶𝗻 𝗨𝘀? By becoming a "Friend of ShareMed," you will: 💊 Support affordable access to medicines. 💰 Significantly reduce healthcare costs. 🌍 Prevent waste and minimize environmental impact. Together, we can make a difference and contribute to a healthier, more sustainable world. 🌿 𝗛𝗼𝘄 𝘁𝗼 𝗝𝗼𝗶𝗻: If you are interested in supporting our mission, visit our homepage and register under the 𝗙𝗿𝗶𝗲𝗻𝗱𝘀 𝗼𝗳 𝗦𝗵𝗮𝗿𝗲𝗠𝗲𝗱 tab (https://lnkd.in/eKTXchYs). We look forward to welcoming you to our community and featuring your photo and profile in our gallery of supporters. Join us today and be a part of something meaningful. Together, we can transform lives and protect our planet. Visit our homepage, ShareMed Swiss (https://lnkd.in/eVM9dNS2) and register now! And don't forget to spread the word! 😉 Thank you for your support and commitment. Warm regards, The ShareMed Swiss Team #MedicalAccess #Sustainability #MedicineDonation #SupportNetwork #EnvironmentalImpact #ShareMedSwiss #FriendsOfShareMed #JoinUs #MakeADifference

30

14 Kommentare

🧐 Beyond the Average Patient: Integrating Population Diversity to Revolutionize Liver Safety in Drug Development at #IHICallDays Our Head of External Collaborations and Co-founder, Dr. Wolfgang Moritz will attend the Brokerage event for Innovative Health Initiative (IHI)’s 2025 calls from November 12 to 14 in Brussels, where he will present InSphero’s innovative approach to enhance population diversity in #preclinical research. 🔬 By using human liver microtissues from a wide range of human donors—including varying ages, sexes, races, and liver health profiles—we’re addressing gaps in #drugsafety that can lead to unexpected #livertoxicity in diverse populations. 🚀 Our approach involves testing compounds known to cause drug-induced liver injury (#DILI), applying pathology and biomarker profiling, and even developing an #AI-assisted DILI prediction scoring tool to identify high-risk profiles early. 🤩 Aligned with #IHICallDays, this initiative not only promotes patient safety but aims to create safer, more effective therapies across diverse populations. Excited to lead this next chapter in patient-centered drug development! 📅 Would you like to learn more and join our initiative? Register for the event via the link in comments 👇 Jan Lichtenberg Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Arnab China, Ph.D. Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Tina Žel Rositsa Hadzhipetrova

19

3 Kommentare

Exciting News: myriamed GmbH ´s Arne Östlind is attending the health.tech conference in munich from 05-06.2024 ! myriamed GmbH´s ultimate aim is to contribute to the development of new cures for today‘s most debilitating diseases by defining wanted and unwanted drug effects at the earliest possible time point. With 20+ years of experience in cell and engineered muscle models we are determined to provide our customers with standardized and individualized solutions to move preclinical drug development closer to clinical reality. myriamed GmbH´s wholly human platforms allow for detailed mode of action analyses and a rationale dosing strategy for early clinical trials. This is particularly useful in cases where animal models largely fail, i.e., in the development of new therapies targeting specific human molecules (protein, RNA, DNA). Want to meat Arne Östlind in person and talk about the myriamed GmbH approach? Just use the health tech app: https://lnkd.in/dz-wqwHr or contact us via the myriamed GmbH website. More about myriamed GmbH: www.myriamed.com More about the health.tech conference: https://www.health.tech/

33

1 Kommentar

⏰ Reminder to all startups in #medtech, #diagnostics, #pharma, and #labsystems! Don't let this opportunity slip away. Apply now for the Helbling Technik Venture Challenge, in partnership with Venturelab. 💡 This is your chance to win a consulting package valued at CHF 25,000 for due diligence or product development. 👇 Apply before the 21st of April! #WomenAndBeyondInMedteCH #SwissStartups #Helbling #Medtech #Diagnostics #LabSystems

3

At Sandoz, we believe that driving biosimilar adoption can support more equitable access to high-quality healthcare and improve outcomes for patients across the globe. We’re excited about the opportunity to foster Day 1 access to generics and biosimilars in Europe, improve supply chain resilience and simplify the regulatory framework with the ongoing EU Pharma Review 🌍 This week, Rebecca Guntern, President Region Europe and Country President Switzerland, and Peter Stenico, Global Head of Biosimilars and Country President Austria, spoke at Reuters Events Pharma where they shared their insights on the importance of revising the EU pharmaceutical legislation, regulatory streamlining, and the adoption of smarter procurement processes to increase access to generics and biosimilars in Europe. See below for some key takeaways from Rebecca and Peter 👇 #Biosimilars #Healthcare #REPharma2024 http://bit.ly/43Qc64c

606

2 Kommentare

📖 #ScienceSnack: Status quo and future perspectives of molecular diagnostics in dermatology How well established has molecular diagnostics become within the various disciplines of dermatology in recent years and what are the future perspectives for further development? A review from 2023 by Dermagnostix Co-Founders Christoffer Gebhardt, Kilian Eyerich and Natalie Garzorz-Stark addresses these questions. Swipe through the slides to see the results or read the review via the following link: https://lnkd.in/gsMtVmqm #MolecularDiagnostics #Dermatology

14

#DHC24 Join us on for 𝗗𝗶𝗴𝗶𝘁𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in Berlin next week, a key event addressing the latest trends and challenges in Digital Health. 💡𝗞𝗲𝘆 𝘁𝗼𝗽𝗶𝗰𝘀 𝗼𝗳 #𝗗𝗛𝗖𝟮𝟰 🔹 Digital Health and politics 🔹 AI in Medtech and Pharma 🔹 Advancing Digital Health literacy 🔹 Big Data and its role in Healthcare innovation 🔹 Future health trends Connect with Varvara Bogdanova, Healthcare Innovations Manager at DataArt, to discuss the major trends, challenges, and how to address them. #DigitalHealth #AIinHealthcare #HealthTech #Innovation #Berlin #DataArtHealthcare

21

4SC is headed to the #EORTC Cutaneous Lymphoma Tumour Group (CLTG) Annual Meeting from 9-11 October.   Reach out to us if you would like to meet our Chief Medical Officer Susanne Danhauser-Riedl or Head of Project Management Matthias Borgmann to learn about the #RESMAIN study which investigated the efficacy of #resminostat (#Kinselby) as a maintenance treatment for cutaneous T-cell lymphoma (#CTLC).   #EORTCCLTG #RESMAINstudy #RareDisease #BloodCancer

31

💥Now available: Vaccinovigilance Annual Report 2023 The new report provides a comprehensive overview of adverse events reported after vaccinations in Switzerland in 2023. 📊 Key findings: 💉Over 700 reports related to COVID-19 vaccines 💉Increase in reports for non-COVID vaccines compared to previous years 💉Frequently reported reactions: fever, chills, and local discomfort Swissmedic emphasizes the importance of high-quality reports, which are essential for the early detection of new safety signals. In 2023, evaluations and international collaboration also remained a priority to ensure vaccine safety. 👉 The full report is now available online: https://bit.ly/3EWEeFg #Swissmedic #Vaccinovigilance #VaccineSafety

1

Big step bringing metabolic health self-assessment to a broader audience

7